In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque

Executive Summary

What's the value of a well-documented set of clinical samples in the atherosclerosis business? For Merck, about $150 million. For FoxHollow, funding and validation for its contrarian device model.
Advertisement

Related Content

Januvia: Defining Primary-Care Success and Risk
Januvia: Defining Primary-Care Success and Risk
Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.
Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.
FoxHollow Makes First Acquisition, Buys Kerberos
FoxHollow Makes First Acquisition, Buys Kerberos
FoxHollow/Merck R&D Deal: The Value of Plaque
FoxHollow/Merck R&D Deal: The Value of Plaque
FoxHollow: Reviving Atherectomy
FoxHollow: Reviving Atherectomy

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel